Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 15, 2009Clinical Cancer ResearchOpen Access

Combined Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor (EGFR) Blockade Inhibits Tumor Growth in Xenograft Models of EGFR Inhibitor Resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

GNGeorge N. NaumovMNMonique B. NilssonTCTina Cascone

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Naumov et al. (2009) studied this question.

synapsesocial.com/papers/69dc31ec3080d3567e274704https://doi.org/10.1158/1078-0432.ccr-08-2904
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent Mechanisms2006 · 268 citations
  2. 2Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer2006 · 5,802 citations
  3. 3Tumor Endothelial Cells Express Epidermal Growth Factor Receptor (EGFR) but not ErbB3 and Are Responsive to EGF and to EGFR Kinase Inhibitors2006 · 219 citations
  4. 4An Alternative Inhibitor Overcomes Resistance Caused by a Mutation of the Epidermal Growth Factor Receptor2005 · 271 citations
  5. 5Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain2005 · 3,556 citations